A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.

Authors: Rodabe Navroze Amaria, Axel Hauschild, Michael Lowe, Janis M. Taube, Adil Daud, Thach-Giao Truong, Sarah A. Weiss, Ankit Mangla, Tapan Miyani, Deidre Williams, Fang Fang, Shuquan Chen, Mark Salvati, Israel Lowy, Rossella Marullo, Matthew G. Fury, Karl Lewis, Humberto Lara-Guerra

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9596

Source: Full article

---

Abstract

TPS9596